One is specific immunotherapy which targets particular antigens in MPM tissue, and the other is a non-specific, but anti-tumor immunotherapy using such cytokines as interleukin 2 (IL-2), tumor necrosis factor (TNF), and interferon (INF) [9]. The gene discussed is CBLIF; the disease is neoplasm.